EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

E3 ligase ligand optimization of Clinical PROTACs

Hanrui Jiang, Huan Xiong, Shuang-Xi Gu, Mingliang Wang

Frontiers in Chemistry · 17.01.2023 · 11

DOI: 10.3389/fchem.2023.1098331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Chemistry, online erschienen am 17.01.2023. Verfasst von Hanrui Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering & Pharmacy, Wuhan Institute of Technology, Wuhan, …. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis targeting chimeras (PROTACs) technology can realize the development of drugs for non-druggable targets that are difficult to achieve with traditional small molecules, and therefore has attracted extensive attention from both academia and industry. Up to now, there are more than 600 known E3 ubiquitin ligases with different structures and functions, but only a few have developed corresponding E3 ubiquitin ligase ligands, and the ligands used to design PROTAC molecules are limited to a few types such as VHL (Von-Hippel-Lindau), CRBN (Cereblon), MDM2 (Mouse Doubleminute 2 homolog), IAP (Inhibitor of apoptosis proteins), etc. Most of the PROTAC molecules that have entered clinical trials were developed based on CRBN ligands, and only DT2216 was based on VHL ligand. Obviously, the structural optimization of E3 ubiquitin ligase ligands plays an instrumental role in PROTAC technology from bench to bedside. In this review, we review the structure optimization process of E3 ubiquitin ligase ligands currently entering clinical trials on PROTAC molecules, summarize some characteristics of these ligands in terms of druggability, and provide some preliminary insights into their structural optimization. We hope that this review will help medicinal chemists to develop more druggable molecules into clinical studies and to realize the greater therapeutic potential of PROTAC technology.

Schlagwörter

Stichwörter der Autor:innen

CRBNE3 ubiquitin ligase ligandPROTACsclinical trialsstructure optimization

Autor:innen und Institutionen

  • Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering & Pharmacy, Wuhan Institute of Technology, Wuhan, China.
  • Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China.
  • Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Zitieren

APA

Jiang, H., Xiong, H., Gu, S. X., & Wang, M. (2023). E3 ligase ligand optimization of Clinical PROTACs. Frontiers in Chemistry, 11. https://doi.org/10.3389/fchem.2023.1098331

Vancouver

Jiang H, Xiong H, Gu SX, Wang M. E3 ligase ligand optimization of Clinical PROTACs. Frontiers in Chemistry. 2023;11. doi:10.3389/fchem.2023.1098331

BibTeX
@article{Jiang2023,
  author = {Jiang, Hanrui and Xiong, Huan and Gu, Shuang-Xi and Wang, Mingliang},
  title = {E3 ligase ligand optimization of Clinical PROTACs},
  journal = {Frontiers in Chemistry},
  year = {2023},
  volume = {11},
  doi = {10.3389/fchem.2023.1098331}
}
Kostenlos starten →